Duality Advisers, LP Madrigal Pharmaceuticals, Inc. Transaction History

Duality Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$55.89 - $101.89 $587,851 - $1.07 Million	-10,518 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$72.34 - $95.09 $266,572 - $350,406	-3,685 Reduced 25.95%	10,518 $891,000
Q3 2021 Nov 08, 2021	SELL	$78.35 - $105.02 $261,062 - $349,926	-3,332 Reduced 19.0%	14,203 $1.13 Million
Q2 2021 Aug 09, 2021	BUY	$97.2 - $137.59 $1.7 Million - $2.41 Million	17,535 New	17,535 $1.71 Million
Q1 2021 May 13, 2021	SELL	$108.54 - $125.2 $986,194 - $1.14 Million	-9,086 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$110.06 - $133.7 $1 Million - $1.21 Million	9,086 New	9,086 $1.01 Million

298

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.76B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.